The Latest Clinical Trial for Nintedanib – Are You a Candidate?

February 24, 2017

Scientists and researchers are excited over the latest completion of a Phase II clinical trial for those suffering from mesothelioma – an incurable asbestos-caused cancer that has a median survival of only 9 to 12 months.  The LUME-Meso Phase II trial for patients with malignant pleural mesothelioma showed a slight increase in progression-free and overall…

Read More

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

February 22, 2017

Purpose The NCI Surgery Branch has developed an experimental therapy for treating patients with metastatic cancer that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying these specific cells with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells back to the patient. This type of therapy is called gene transfer. In this protocol, we are modifying the patient s white blood cells with a retrovirus that has the gene for anti-mesothelin incorporated in the retrovirus.

Read More

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer

February 15, 2017

Purpose: The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC), and other B7-H3 expressing cancers. The study will also evaluate what is the highest dose of enoblituzumab that can be given safely when given with pembrolizumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of MGA271 in combination with pembrolizumab.

Read More

Lack of Treatment Responses for Mesothelioma, Proteins Combat Metastasis

February 13, 2017

Mesothelioma is an incredibly difficult cancer to treat. Its late stage diagnosis coupled with its aggressive nature leaves victims without very much time to combat this fatal cancer. There are a variety of treatment options available to those suffering from mesothelioma, even though there is no cure. Surgery Radiation Chemotherapy Intraoperative photodynamic therapy Immunotherapy Gene…

Read More

A Study of ABBV-181 in Participants With Advanced Solid Tumors

February 8, 2017

Purpose: This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181. The study will consist of 2 parts: ABBV-181 dose escalation and ABBV-181 dose expansion.

Read More

Lung-Sparing Surgery Dramatically Improves Prognosis for Mesothelioma Patients

January 31, 2017

Those suffering from mesothelioma know that the prognosis is grim. The average life expectancy for someone who is recently diagnosed is only eight months. Chemotherapy is the standard treatment for mesothelioma, but in most cases, the cancer is too far advanced for chemotherapy to be effective. Surgery for mesothelioma is possible but results from surgery…

Read More

Phase IB of Selinexor in Combination With Standard Chemotherapy in Patients With Advanced Malignancies

January 25, 2017

Purpose: Primary Objective: To establish the safety and tolerability of Selinexor when given in combination with standard chemotherapy regimens.

Secondary Objectives:To determine disease control and progression free survival of Selinexor administered with standard chemotherapy treatments.

Exploratory Objectives:To determine the correlation of translational biomarkers To compare serial assessment of mutation status in biopsies obtained at baseline and progression after clinical response to combination therapy

Read More